Martin Dow is a Pakistani multinational pharmaceutical company which is based in Karachi. It was founded in 1995[3][4] and has six manufacturing facilities in Pakistan[5] and one in France.[6]
History
Martin Dow was founded in 1995 and began operations in 2000 with a small manufacturing facility in Lahore.[7]
In 2010, Martin Dow acquired the manufacturing facility and brands of Roche Pakistan.[8]
In 2015, Martin Dow was recognized as a Global Growth Company by the World Economic Forum.[9] In the same year, Martin Dow entered into an alliance with Biocodex S.A., a France-based pharmaceutical company.[10]
In 2016, German Merck KGaA executed a binding contract to divest its shareholding in Pakistan to Martin Dow Ltd.[11][12][13]
In 2016, in a €1.5 million deal, Martin Dow acquired the Laboratoires Salem (before 2010 Bristol-Myers Squibb) pharmaceutical manufacturing facility in Meymac, France.[14][15] In March 2017, the French President Francois Hollande inaugurated Martin Dow Pharma's Meymac Plant in France.[16][17] The plant of V2Pharm in Gien, France was also taken over by Martin Dow.[18]
In 2020, Martin Dow was awarded for excellent performance in fire safety and protection by the Sindh local government minister.[19]
Controversy
In 2016, the National Accountability Bureau (NAB) arrested two directors of Martin Dow because it wrongfully derived financial benefits on the basis of illegal price increase.[20][21][22]
References
^"Martin Dow Limited"(PDF). The Pakistan Credit Rating Agency Limited. Retrieved 29 February 2024.
^bhooto, bilawal (21 November 2016). "A strategic relationship". Dawn. Retrieved 31 December 2016. With the acquisition of Merck Pakistan, Martin Dow will have six manufacturing facilities in the country.
^"Pakistani pharmaceutical company to operate in France". Business Recorder. 21 August 2016. Retrieved 30 December 2016. A Pakistani Pharmaceutical company, Martin Dow has acquired a pharmaceutical manufacturing facility in Meymac, France. The facility was earlier owned by the renowned pharmaceutical firm Bristol-Myers Squibb.
